No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt
Major banks rating｜Goldman Sachs: Raises UNITED LAB's Target Price to HKD 10.25 and increases sales and profit forecasts.
Goldman Sachs released a report indicating that, according to Wind data, UNITED LAB's penicillin G and 6-APA maintain favorable pricing and are at historically high levels, although the price of 6-APA experienced some slight fluctuations in November. The firm expects that the company's pricing trends will remain resilient over the next few quarters, as a major pharmaceutical manufacturer in India is expanding its capacity at a slower-than-expected pace. Goldman Sachs stated that due to a more positive outlook on the company's pricing trends for next year, it raised the sales and profit forecasts for 2025 and 2026 by 8.1%/4.7% and 17.4%/10%, respectively, with the Target Price increased from HKD 9.31 to 10.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Hong Kong stock movement | united lab (03933) rose over 3% as its anti-infection product mupirocin ointment has recently been approved for market launch.
United Lab (03933) rose more than 3%, as of the time of publication, up 3.73%, at 11.68 Hong Kong dollars, with a turnover of 30.4787 million Hong Kong dollars.
No Data
